Prescription Medication and Illicit Drug Testing in the Outpatient Setting
Defines coverage criteria, limitations, and documentation/reimbursement rules for outpatient presumptive and definitive drug testing (primarily urine/oral fluid) for clinical purposes; applies to Healthfirst members and outpatient providers in North Carolina. This part covers indications, specimen types, frequency limits, and prohibited testing practices.
Added new 'General' section and new CC6 stating that presumptive drug screening and definitive drug testing do not meet coverage criteria in situations not addressed elsewhere.
Added CPT codes 0517U, 0518U, 0519U, 0520U (effective 10/1/2024) as coding modifications.
Removed former C and E in disclaimer within section III and adjusted numeric formatting (CC1 and CC2) to written words for consistency.
Updated the background, guidelines and recommendations, and evidence-based scientific references without changing coverage criteria.
Coverage Criteria for Presumptive and Definitive Drug Testing
Presumptive Urine Drug Screening — Covered Indications
Presumptive urine drug screening MEETS COVERAGE when ANY of the following apply:
Random testing interval and drug selection must be based on history and documented in the medical record.
Obtain informed consent and consider validated verbal screening tools per ACOG guidance.
Document maternal history or clinical concerns in the record.
Testing should be documented as part of pre-transplant evaluation.
Use testing to inform diagnosis/management in context of clinical assessment.
Consider drug interactions (e.g., cocaine with antiepileptics) as rationale for testing.
Frequencies must be documented in the patient medical record.
Use testing alongside clinical assessment to guide evaluation.
Definitive Drug Testing — Covered Indications
Definitive/confirmatory testing MEETS COVERAGE when ALL of the following are met:
Documentation of medical necessity required in the patient's record.
Each condition supports coverage when the overall 'all' requirement (documented rationale and ≤7 classes) is met.
Use of definitive vs presumptive testing
Covered when meeting clinical justification for accurate identification or monitoring:
Consensus recommendation (Argoff et al. 2018) — definitive testing preferred for accuracy and confirmation.
Monitoring frequency by risk level
Perform UDM at the following minimum frequencies:
Frequencies reflect consensus recommendations (Argoff et al., AMDG) and should be individualized by clinical judgment.
Clinical scenarios where testing may inform management
Testing may be useful in specific situations:
Evidence and observational studies support selective use in these scenarios rather than universal screening.
Risk-stratified UDT frequency and monitoring
Covered/appropriate when meeting risk-based monitoring and clinical judgment criteria
Baseline and ongoing monitoring
- Risk‑stratified frequency: Low‑risk: at least annually (or every 6–12 months per AAFP); Moderate‑risk: 2 or more times per year (or every 3–6 months per AAFP); High‑risk: 3 or more times per year (or every 1–3 months per AAFP/AMDG guidance).low=annual; moderate=2+; high=3+
Frequencies vary by guideline; apply clinical judgment.
Testing modality and confirmation
Use of definitive vs presumptive testing
AACC and Argoff consensus recommend definitive testing for accuracy and confirmation.
CDC, AACC acknowledge immunoassay use with caveats; confirm unexpected results with definitive methods.
Testing frequency by patient risk
Testing frequency guidance from cited organizations (expressed as ranges and context-specific recommendations):
Sources include Washington State AMDG, ASAM, Texas Pain Society, SAMHSA; frequencies differ by context and setting.
Modality and confirmatory testing
Guidance on test modality and confirmatory testing:
ASAM and SAMHSA recommend definitive testing to confirm unexpected or consequential results and when results will inform major clinical decisions.
Specimen types and mandated analytes
Specimen types and mandated analytes in federal guidance:
Consider matrix suitability and regulatory requirements when selecting specimen type; oral fluid testing has specific HHS rules.
Coverage stance and clinically appropriate use
Key coverage stance and clinical-use considerations from the document
Added as a general default non‑coverage statement in the policy revision history.
Contextual recommendations from WHO and clinical societies; interpret tests in clinical context and confirm as appropriate.
Reflects ACOG and other guidance on consent and confirmatory testing.
General - Default non-coverage
Policy-level clarification added:
Added to establish default non‑coverage for situations not specifically enumerated in the policy.
Definitive drug testing panels that exceed 7 drug classes do not meet coverage criteria; similarly, testing using proprietary panels (for example, CareView360) is not covered. Specimen validity testing (such as urine specific gravity, creatinine, pH, oxidant level, or genetic identity testing) is expressly excluded from coverage. Providers should plan testing within the policy limits (≤7 classes for definitive tests) and avoid ordering proprietary or specimen‑validity assays that will likely be denied or not reimbursed.
Operational notes: only urine or oral fluid specimens are generally covered (blood covered only for anuric chronic renal failure), and confirmatory/definitive testing must be supported by documentation of clinical rationale in the patient’s medical record. Same‑day duplicate testing of the same analyte from different specimens and blanket or standing orders for all patients are not reimbursed.
For most acute clinical encounters, routine drug‑of‑abuse (DOA) monitoring has limited value and may be unnecessary. Evidence cited in the policy indicates DOA testing is most useful in specific settings (for example, drug‑treatment programs, pain management, or psychiatric evaluation) rather than as a blanket screen in acute care. Large retrospective and other studies referenced found limited utility of routine screening in many acute settings, and some routine screens may be wasteful.
When DOA testing is considered in acute contexts, it should be targeted to situations where results would meaningfully change management (e.g., unexplained acute psychosis, pre‑administration checks with drug interactions, seizure evaluation), not performed as routine screening for all patients.
Quantitative definitive urine testing should not be used routinely to evaluate dose adjustments or to assess adherence to a prescribed dosing regimen. The AACC and related guidance indicate that quantitative definitive testing is not generally more useful than qualitative definitive testing for routine outcomes in pain management and should be reserved for complex cases (for example, suspected variant metabolism, spiked samples, multiple opioids, or to rule out alternative exposure sources).
When precise concentrations are clinically necessary (rare, complex scenarios), quantitative definitive testing can be justified, but routine dosing or adherence decisions should not rely on quantitative urine levels alone.
Guidelines do not reach uniform agreement on routine urine drug testing: some organizations recommend testing only for high‑risk patients, others (for example, certain workers’ compensation programs) may require mandatory UDT, and many recommend weighing pros and cons based on clinical context. Clinicians should apply guideline recommendations and local regulatory requirements and document the rationale when electing to test.
Routine or universal urine drug testing in pregnancy is controversial. ACOG recommends using validated verbal screening tools (for example, 4Ps, NIDA Quick Screen, CRAFFT) rather than routine UDT and emphasizes informed consent and compliance with state law. When testing is performed in obstetric care, providers must understand test limitations and request confirmatory mass‑spectrometry testing as appropriate.
This policy clarifies that situations not specifically addressed in the coverage criteria are excluded: presumptive and definitive drug testing for unenumerated indications do not meet coverage criteria. Definitive testing for panels >7 drug classes, proprietary tests, and specimen validity testing are explicit examples of non‑covered situations.
Providers should verify coverage against member benefits and applicable state/federal rules before ordering tests outside the listed covered indications, as such orders may be denied.
Reiteration of policy default: unless an indication is specifically listed as covered, presumptive drug screening and definitive drug testing do not meet coverage criteria. Routine blanket orders or standing orders for all patients are not reimbursed, and providers should avoid ordering tests without documented medical necessity.
Psychiatric pre‑administration screening for acetaminophen or salicylates was evaluated in a large multicenter retrospective VA study and was found to be unnecessary and wasteful. This supports the policy stance that routine, untargeted toxicology screening in psychiatric pre‑administration settings is not routinely indicated.
Routine quantitative definitive urine testing for the purpose of evaluating medication dosage or general adherence is not generally useful and is therefore not covered for routine monitoring. Definitive (qualitative) testing is preferred for confirmation of unexpected results or when specific identification will change management; quantitative testing is reserved for specialized or complex clinical questions.
Clinical guidelines vary in their endorsement of routine or universal testing: some recommend testing only for higher‑risk patients while others provide more prescriptive frequencies or requirements. Consensus documents recommend baseline testing and risk‑stratified periodic monitoring rather than universal routine testing; apply clinical judgment and document decisions in the medical record.
Policy restatement: testing not specifically listed as covered is not covered. The recently added General section formalizes this default non‑coverage position—providers must ensure testing aligns with one of the enumerated covered indications and is documented appropriately to support reimbursement.
Additional operational note: per the policy addendum and revision history, presumptive and definitive testing for any situations not enumerated in the policy do not meet coverage criteria. This reiteration reinforces that unenumerated uses are excluded and may be denied.
Coding and Reimbursement Codes
| Any AMA definitive drug class codes | Specifically listed as not reimbursed |
| Same-day duplicate testing | Same day testing of the same drug or metabolites from two different samples (e.g., both a blood and a urine specimen) is not reimbursed |
| 80305 | Drug test(s), presumptive, any number of drug classes; direct optical observation (eg, immunoassay) |
| 80306 | Drug test(s), presumptive, any number of drug classes; instrument assisted direct optical observation (eg, immunoassay) |
| 80307 | Drug test(s), presumptive, any number of drug classes; instrument chemistry analyzers, chromatography, and mass spectrometry |
| 0007U | Drug test(s), presumptive, with definitive confirmation of positive results, urine, includes specimen verification |
| 0011U | Prescription drug monitoring, LC-MS/MS, oral fluid, reported vs estimated steady-state range |
| 0051U | Prescription drug monitoring, LC-MS/MS, urine, 31 drug panel, quantitative |
| 0054U | Prescription drug monitoring, 14+ classes, definitive tandem MS with chromatography, capillary blood, quantitative |
| 0079U | Comparative DNA analysis using selected SNPs, urine and buccal DNA, for specimen identity verification |
| 0082U | Drug test(s), definitive, 90+ drugs, definitive chromatography with mass spectrometry, plus presumptive immunoassay |
| 0093U | Prescription drug monitoring, evaluation of 65 common drugs by LC-MS/MS, urine |
| 0227U | Drug assay, presumptive, 30 or more drugs or metabolites |
| 0328U | Drug assay, definitive, 120+ drugs and metabolites, urine, quantitative LC-MS/MS |
| 0517U | Therapeutic drug monitoring, 80+ psychoactive drugs, LC-MS/MS, plasma, qualitative and quantitative |
| 0518U | Therapeutic drug monitoring, 90+ pain and mental health drugs, LC-MS/MS, plasma, qualitative and quantitative |
| 0519U | Therapeutic drug monitoring, medications specific to pain, depression, anxiety, LC-MS/MS, plasma, 110+ drugs |
| 0520U | Therapeutic drug monitoring, 200+ drugs or substances, LC-MS/MS, plasma, qualitative and quantitative |
| G0480 | Drug test(s), definitive, GC/MS or LC/MS methods, specimen validity testing, 1-7 drug classes |
| G0481 | Drug test(s), definitive, GC/MS or LC/MS methods, specimen validity testing, 8-14 drug classes |
| G0482 | Drug test(s), definitive, GC/MS or LC/MS methods, specimen validity testing, 15-21 drug classes |
| G0483 | Drug test(s), definitive, GC/MS or LC/MS methods, specimen validity testing, 22+ drug classes |
| G0659 | Drug test(s), definitive, performed without method- or drug-specific calibration or matrix-matched QC; any number of drug classes |
Provider Responsibilities, Documentation, and Billing Guidance
Benefit verification required
Verify member benefits and applicable rules before ordering/testing. Coverage depends on the member's benefit plan, and Medicare/Medicaid specifications may impose additional requirements. Confirm whether the requested presumptive or definitive drug testing is a covered service for the member and obtain any required prior authorization per payer rules before performing testing.
- Benefit verification required prior to testing
- Coverage depends on evidence of coverage and state/federal rules
Step therapy
No formal step therapy rules for drug testing are specified in this excerpt. Use clinical judgment and follow payer/institutional requirements when selecting testing modalities.
- No step therapy specified in policy excerpt
When to obtain definitive confirmatory testing
Obtain definitive (confirmatory) testing when presumptive or immunoassay results are unexpected or will influence consequential clinical or non-clinical decisions (for example, before stopping or initiating opioids, taking disciplinary or legal actions, or when results are inconsistent with clinical expectations). Document clinical rationale for confirmatory testing in the medical record.
- Definitive testing recommended for unexpected/incongruent results
- Confirmatory testing should be supported by documentation of rationale
HHS oral fluid testing and allowed additional testing
HHS allows oral fluid testing where federal workplace testing applies and authorizes additional drug and specimen validity testing on oral fluid on a case-by-case basis (including testing for marijuana and cocaine and other Schedule I/II drugs per panel). MRO-requested validity testing and biomarker tests may be permitted; abnormal specimens may warrant additional testing. Ensure compliance with HHS requirements when using oral fluid specimens.
- Oral fluid specimens must be tested for marijuana and cocaine per HHS panel
- HHS permits additional drug/validity/biomarker testing on oral fluid on a case-by-case/MRO request
Procedure codes listed — verify coding and authorization
Verify appropriate procedure codes when ordering and billing. Use the listed presumptive and definitive CPT/HCPCS/CPT-unique codes and ensure correct code selection, modifier use, and prior authorization as required by the payer. Off-cycle/additional CPT codes added (0517U–0520U and other proprietary codes) must be used correctly.
Failure to perform urine drug screening
For worker's compensation or states with specific rules, failure to perform urine drug screening prior to initiating chronic opioid therapy (where required) may conflict with state WC guidelines and could affect care decisions. Perform required pre-treatment UDS when mandated by applicable WC or state rules.
- UDS before starting chronic opioid therapy is required/recommended in some WC programs (e.g., Wisconsin)
- Failure to perform may conflict with state worker's compensation guidance
When used, UDT results and patient education
When used for monitoring, document how UDT results were used in clinical care and provide patient education about testing purpose, interpretation limits, and implications. Include counseling, follow-up plans, and any behavior-change interventions resulting from results.
- Document use of UDT results in monitoring programs and patient education provided
- Educate patients that UDTs have limitations and are one part of clinical assessment
Document comprehensive screening and risk assessment
Document comprehensive screening and risk assessment before and during opioid therapy: include screening tools, full history, PDMP query, urine toxicology results (when performed), risk stratification, treatment goals, opioid agreements, and referrals when high risk. Ensure documentation supports medical necessity for testing.
- Record screening, history, PDMP query, UDT results, risk stratification, and treatment goals
- Refer to specialists for high-risk patients per recommendations
Consent and confirmatory testing
Obtain informed consent when appropriate and be aware of test characteristics and limitations. For unexpected or consequential immunoassay results, request confirmatory testing with mass spectrometry (GC-MS, LC-MS/MS) or other definitive methods. Record consent, test choice, and confirmation rationale in the medical record.
- Obtain patient consent where required and document it
- Request mass-spec confirmation for unexpected or consequential results
Determination basis
Reimbursement and coverage determinations are based on applicable evidence of coverage, state and federal regulations, provider agreements, and adherence to this policy and coding/billing rules. Failure to follow coding, billing, and reimbursement guidelines may result in claim denials or recoupment.
- Coverage decisions rely on member EOC and state/federal rules
- Noncompliance with coding/billing policies may lead to denial/recoupment
Initial POC immunoassay then confirm as needed
Algorithmic testing approach: consider initial point-of-care (POC) or laboratory immunoassay presumptive testing for baseline and monitoring. If results are inconsistent with expectations or clinically significant, follow with definitive confirmatory testing (GC-MS, LC-MS/MS) per guidance and document the rationale.
- Initial POC/lab immunoassay for baseline screening and monitoring
- Use definitive confirmatory testing when indicated
Level-of-Care Specific Criteria
Outpatient substance use treatment/monitoring
Document rationale and results in the medical record.
Outpatient
Document assessment, PDMP checks, and monitoring plan in the chart.
Opioid Treatment Program / Substance Use Disorder treatment
SAMHSA recommends these minimum analytes for OTP admission; document results.
Outpatient
WHO recommends UDT in emergency cases when patient history is unavailable.
Treatment Modalities and Monitoring Programs
Medication-assisted monitoring / Opioid therapy monitoring
Random testing interval and selected drugs must be based on history and documented.
UDM (Urine Drug Monitoring)
Argoff consensus supports definitive testing as most accurate; document testing approach.
Medication monitoring and OUD linkage
CDC and ASIPP recommend using results to improve patient safety and linkage to treatment rather than punitive measures.
Toxicology testing (presumptive and definitive)
ASAM and SAMHSA recommend definitive testing for confirmation and major clinical decisions.
Screening and monitoring
OASAS and ASAM guidance emphasize clinical integration and appropriate panel selection.
Toxicology use in addiction treatment
These sources inform clinical practice but do not alone define coverage; follow documentation and payer rules.
Definitions and Test Methodology
Background and Evidence Summary
Background: drug misuse is common, and urine is the most frequently used specimen for outpatient drug testing. This policy applies to outpatient clinical toxicology testing (primarily urine and oral fluid), addressing indications, specimen types, frequency limits, and testing practices; it does not apply to forensic testing or routine therapeutic drug monitoring outside the specified clinical contexts.
Policy Revision History and Changes
Reviewed and updated background, guidelines, recommendations, and evidence-based references; editorial clarifications made (removed former C and E in disclaimer, changed numerals to words for consistency); added new 'General' section CC6 establishing that presumptive drug screening and definitive drug testing do not meet coverage criteria in situations not otherwise addressed.
Off-cycle coding modification added CPT codes 0517U, 0518U, 0519U, and 0520U (effective 2024-10-01) to the list of applicable procedure codes.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.